Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that three scientific presentations in dementia-related psychosis (DRP) will be shared at the Alzheimer’s Association International Conference® 2021 (AAIC®), being held July 26-30, 2021 in Denver, Colo., and virtually.

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that three scientific presentations in dementia-related psychosis (DRP) will be shared at the Alzheimer’s Association International Conference® 2021 (AAIC®), being held July 26-30, 2021 in Denver, Colo., and virtually.

Just a month after it gave the new Alzheimer's drug aducanumab (Aduhelm) the green light, the FDA decided to change the label.

Alzheimer’s patients and their loved ones have a renewed sense of hope now that the U.S. Food & Drug Administration approved the first Alzheimer’s drug in nearly two decades.

The FDA’s approval of Biogen’s Alzheimer’s drug Aduhelm was a landmark moment in the life of Dr. Paul Aisen.

Now that the FDA has approved Biogen's aducanumab (Aduhelm), the controversial new drug for Alzheimer's disease, what does this mean?

In a watershed moment for the field, the U.S. Food and Drug Administration yesterday approved the first Alzheimer’s treatment that tackles the underlying disease pathology.

The Food and Drug Administration (FDA) approved Biogen's aducanumab on June 7, making it the first Alzheimer's medication available in nearly 20 years and the only one that could slow the progression of the disease.